Evidence map›Paper›PMID 31893951›Full record

Trial reportCartilage2021

Matrix-Associated Autologous Chondrocyte Implantation with Spheroid Technology Is Superior to Arthroscopic Microfracture at 36 Months Regarding Activities of Daily Living and Sporting Activities after Treatment.

Arnd Hoburg, Philipp Niemeyer, Volker Laute, Wolfgang Zinser, Christoph Becher, Thomas Kolombe, Jakob Fay, Stefan Pietsch, Tomasz Kuźma, Wojciech Widuchowski and 1 more

Open access · bronzeAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cartilage, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Arnd HoburgJoint and Spine Centre Steglitz, Berlin, Germany.ORCID 0000-0001-5907-1100
Philipp NiemeyerDepartment of Orthopedic Surgery and Traumatology, University Hospital, Freiburg, Germany.
Volker LauteJoint and Spine Centre Steglitz, Berlin, Germany.
Wolfgang ZinserDepartment of Orthopedic Surgery and Traumatology, St. Vinzenz-Hospital, Dinslaken, Germany.
Christoph BecherDepartment of Orthopedic Surgery, Medical University Annastift, Hannover, Germany.
Thomas KolombeTraumatology and Reconstructive Surgery, DRK Hospital, Luckenwalde, Germany.
Jakob FayDepartment of Traumatology and Arthroscopic Surgery, Lubinus Clinicum, Kiel, Germany.
Stefan PietschDepartment of Orthopedic Surgery and Traumatology, Rudolf Elle Hospital, Eisenberg, Germany.
Tomasz KuźmaDepartment of Orthopedic Surgery and Traumatology, Center of Sports Medicine, Orthopedic Clinic, Warsaw, Poland.
Wojciech WiduchowskiHospital of Orthopedics and Trauma Surgery, Piekary Slaskie, Poland.
Stefan FickertSporthopaedicum Straubing, Straubing, Germany.
Heidelberg University · DEMedizinische Hochschule Hannover · DEProsper Hospital · DEUniversity Medical Center Freiburg · DEWaldkrankenhaus Rudolf Elle · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveMatrix-associated autologous chondrocyte implantation (ACI) and microfracture (MF) are well-established treatments for cartilage defects of the knee. However, high-level evidence comparing microfracture and spheroid technology ACI is limited.

designProspective, phase III clinical trial with patients randomized to ACI (

resultsBoth ACI and MF showed significant improvement over the entire 3-year observation period. For the overall KOOS, noninferiority of ACI (the intended primary goal of the study) was formally confirmed; additionally, for the subscores "Activities of Daily Living" and "Sport and Recreation," superiority of ACI over MF was shown at descriptive level. Occurrence of adverse events were not different between both treatments (ACI 77%; MF 74%). Four patients in the MF group required reoperation which was defined as treatment failure. No treatment failure was reported for the ACI group.

conclusionsPatients treated with matrix-associated ACI with spheroid technology showed substantial improvement in various clinical outcomes after 36 months. The advantages of ACI compared with microfracture was underlined by demonstrating noninferiority, in overall KOOS and superiority in the KOOS subscores "Activities of Daily Living" and "Sport and Recreation." In the present study, subgroups comparing different age groups and defect sizes showed comparable clinical outcomes.

Indexed as

Cartilage, ArticularFractures, StressActivities of Daily LivingChondrocytesHumansProspective StudiesTechnologyTransplantation, Autologousautologous chondrocyte implantationcartilagemicrofracturerandomized clinical trialspheroids

Identifiers

PMID31893951
PMCPMC8808956
OpenAlexW2997743867

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.